These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 29225057)

  • 21. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    McGinley KF; Sun X; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    Int J Urol; 2017 Aug; 24(8):611-617. PubMed ID: 28589550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
    Lee H; Lee IJ; Byun SS; Lee SE; Hong SK
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1117-e1122. PubMed ID: 28843377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
    Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
    Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
    Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
    J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
    J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
    Doshi C; Vacchio M; Attwood K; Murekeyisoni C; Mehedint DC; Badkhshan S; Azabdaftari G; Sule N; Guru KA; Mohler JL; Kauffman EC
    Prostate; 2016 Jun; 76(8):715-21. PubMed ID: 26880312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy.
    ElShafei A; Nyame Y; Kara O; Badawy A; Amujiogu I; Fareed K; Klein E; Jones JS
    J Urol; 2016 Jun; 195(6):1767-72. PubMed ID: 26724397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance.
    Jo JK; Hong SK; Byun SS; Lee SE; Oh JJ
    World J Urol; 2015 Nov; 33(11):1729-34. PubMed ID: 25809876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
    Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
    J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.